Phosphodiesterase 5 inhibitors treatment of congenital heart disease with pulmonary arterial hypertension
10.3760/cma.j.issn.1673-4408.2010.02.011
- VernacularTitle:磷酸二酯酶5抑制剂治疗先天性心脏病合并肺动脉高压
- Author:
Xiaolei GONG
;
Zhuoming XU
;
Jinfen LIU
- Publication Type:Journal Article
- Keywords:
Phosphodiesterase 5 inhibitors;
Pulmonary arterial hypertension;
Congenital heart disease
- From:
International Journal of Pediatrics
2010;37(2):142-144,185
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary arterial hypertension is common in patients with congenital heart disease.An effective reduction in pulmonary vascular resistance could improve the survival rate in the future.Research in the pathophysiology of pulmonary arterial hypertension shows that phosphodiesterase 5 inhibitors result in pulmonary vasodilation,decrease vascular resistance.Sildenafil,a inhibitor of phosphodiesterase 5 has been permitted to treat pulmonary arterial hypertension oversea now.Phosphodiesterase 5 inhibitors are proved to reduce pulmonary vascular resistance significantly,improve the survival rate in the future and be well tolerated.This review contains the changes of hemodynamics,exercise tolerance,side effect and pharmacokinetics of phosphodiesterase 5 inhibitors.
